背景:生姜,一种有效的抗病毒药物,抗炎,和抗氧化剂补救措施,是COVID-19的潜在治疗选择。然而,没有足够的关于生姜和COVID-19的临床证据。我们评估了生姜对COVID-19门诊患者临床和临床特征的疗效和安全性。
方法:在这项随机对照试验中,确诊为COVID-19的门诊患者以1∶1的比例随机分配接受生姜(1,000mg,每天3次,共7天)或安慰剂治疗.主要结果是干预结束后的病毒清除。氧饱和度(SPO2),体温,呼吸频率(RR),入院,并评估了不良事件的发生率.
结果:共有84名患者(42名生姜组,42名对照组)被随机分组。与安慰剂组(42.8%)相比,生姜组(41.6%)的病毒清除率没有统计学上的改善。研究结果表明,SPO2、体温、干预结束时两组间RR无显著差异。影像学发现表明,在生姜组干预的第7天,肺浸润明显减少。与安慰剂组相比,生姜组中SPO2<96%的患者百分比在研究中有所下降。此外,在随访期间,两组患者的入院需求和药物不良事件发生率无差异.
结论:生姜对患者的临床和临床参数没有显著影响。然而,这项干预措施显示了安全的不良事件和减少的肺部浸润.
背景:该试验注册为IRCT20200506047323N1。
BACKGROUND: Ginger, a potent antiviral, anti-inflammatory, and antioxidant remedy, is a potential therapeutic option for COVID-19. However, there was not enough clinical evidence about ginger and COVID-19. We evaluated the efficacy and safety of ginger on clinical and paraclinical features in outpatients with COVID-19.
METHODS: In this randomized controlled trial, the outpatients with confirmed COVID-19 were randomly assigned in a 1:1 ratio to receive ginger (1000 mg 3 times a day for 7 days) or placebo. The primary outcome was viral clearance after the end of the intervention. Oxygen saturation (SPO2), body temperature, respiratory rate (RR), hospital admission, and the incidence of adverse events were also assessed.
RESULTS: A total of 84 patients (42 in the ginger and 42 in the control groups) were randomized. The viral clearance was not statistically improved in the ginger group (41.6%) compared to the placebo group (42.8%). The findings indicated that SPO2, body temperature, and RR had no significant difference between the groups at the end of the intervention. The imaging finding indicated pulmonary infiltrate significantly reduced on the 7th day of the intervention in the ginger group. The percentage of patients with SPO2 <96% in the ginger group decreased over the study compared to the placebo group. Moreover, the need for hospital admission and the incidence of adverse drug events were not different between the groups over the follow-up period.
CONCLUSIONS: Ginger had no significant impact on the clinical and paraclinical parameters of patients. However, this intervention demonstrated a safe profile of adverse events and reduced pulmonary infiltrate.
BACKGROUND: The trial was registered as IRCT20200506047323N1.